---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-108716"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:59.600423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M

## Summary
- Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.
- FY 2025 pro forma net revenue guidance raised to $390-410M; Q4 guidance $115-135M; adjusted EBITDA guidance $220-240M.
- One-time $59.7M tax benefit from NOL carryforwards realization contributed to net income.
- Melinta acquisition closed Aug 29; integration ahead of schedule with ~$30M annual synergy run-rate expected by end 2025.
- Cash and short-term investments $55.7M at Sept 30; projecting year-end ~$100M; Phase III ReSPECT enrollment completed.

## SEC filing metadata
- accession: 0001213900-25-108716
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/0001213900-25-108716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea0265136-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-108716
- JSON: https://secwatch.observer/filing/0001213900-25-108716.json
- Plain text: https://secwatch.observer/filing/0001213900-25-108716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.